Cited by 901Cardiac Ischemia and ReperfusionDiabetes Treatment and ManagementAcute Myocardial Infarction Research

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion

Nikolaidis, Lazaros A., Mankad, Sunil, Sokos, George G., Miske, Glen, Shah, Ankur, Elahi, Dariush, Shannon, Richard P.·2004·Circulation

DOI 10.1161/01.cir.0000120505.91348.58

Open this paper in CoChat — free account

Abstract

Background— Glucose-insulin-potassium infusions are beneficial in uncomplicated patients with acute myocardial infarction (AMI) but are of unproven efficacy in AMI with left ventricular (LV) dysfunction because of volume requirements associated with glucose infusion. Glucagon-like peptide-1 (GLP-1) is a naturally occurring incretin with both insulinotropic and insulinomimetic properties that stimulate glucose uptake without the requirements for concomitant glucose infusion. Methods and Results— We investigated the safety and efficacy of a 72-hour infusion of GLP-1 (1.5 pmol/kg per minute) added to background therapy in 10 patients with AMI and LV ejection fraction (EF) <40% after successful primary angioplasty compared with 11 control patients. Echocardiograms were obtained after reperfusion and after the completion of the GLP-1 infusion. Baseline demographics and background therapy were similar, and both groups had severe LV dysfunction at baseline (LVEF=29±2%). GLP-1 significantly improved LVEF (from 29±2% to 39±2%, P <0.01), global wall motion score indexes (1.94±0.11→1.63±0.09, P <0.01), and regional wall motion score indexes (2.53±0.08→2.02±0.11, P <0.01) compared with control subjects. The benefits of GLP-1 were independent of AMI location or history of diabetes. GLP-1 was well tolerated, with only transient gastrointestinal effects. Conclusions— When added to standard therapy, GLP-1 infusion improved regional and global LV function in patients with AMI and severe systolic dysfunction after successful primary angioplasty.

Integrity signals

Registry

Crossref · 10.1161/01.cir.0000120505.91348.58

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Recommendations for Quantitation of the Left Ventricle by Two-Dimensional Echocardiography
Schiller, N. B., Shah, P. M., Crawford, M., DeMaria, A. N., Devereux, R. B., Feigenbaum, H., Gutgesell, H. P., Reichek, N., Sahn, D. J., Schnittger, I., et al. (1989) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(89)80014-8 · Cited by 8,110
Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year
Malmberg, K., Rydén, L., Efendic, S., Herlitz, J., Nicol, P., Waldenstrom, A., Wedel, H., & Welin, L. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00126-k · Cited by 1,560
Clinical Prevention of Sudden Cardiac Death by n-3 Polyunsaturated Fatty Acids and Mechanism of Prevention of Arrhythmias by n-3 Fish Oils
Leaf, A., Kang, J. X., Xiao, Y.-F., & Billman, G. E. (2003) · Circulation · doi:10.1161/01.cir.0000069566.78305.33 · Cited by 605
Glucagon-Like Peptides
Drucker, D. J. (1998) · Diabetes · doi:10.2337/diab.47.2.159 · Cited by 598
Metabolic Modulation of Acute Myocardial Infarction
Díaz, R., Paolasso, E., Piegas, L. S., Tajer, C. D., Moreno, M. G., Corvalán, R., Isea, J., Romero, G., & Collaborative Group (1998) · Circulation · doi:10.1161/01.cir.98.21.2227 · Cited by 517
Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal.
D'Alessio, D., Kahn, S., Leusner, C. R., & Ensinck, J. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117225 · Cited by 309
Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction
van der Horst, I. C. C., Zijlstra, F., Hof, A. W. J. V. ’., Doggen, C. J. M., de Boer, M., Suryapranata, H., Hoorntje, J. C. A., Dambrink, J. E., Gans, R. O. B., & Bilo, H. J. G. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00830-1 · Cited by 259
Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7?36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships
Ritzel, R. A., �rskov, C., Holst, J. J., & Nauck, M. A. (1995) · Diabetologia · doi:10.1007/bf00401846 · Cited by 207
Insulin therapy as an adjunct toreperfusion after acute coronary ischemia
Sack, M. N., & Yellon, D. M. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00164-5 · Cited by 105
Glucose-Insulin-Potassium for Acute Myocardial Infarction
Apstein, C. S. (1998) · Circulation · doi:10.1161/01.cir.98.21.2223 · Cited by 95

Show all 15 references

Research works printed but not linked: 4

10.1161/circ.96.4.1074 · DOI
10.1161/circ.98.21.2227 · DOI
10.1161/circ.98.21.2223 · DOI
1987, Am Heart J, 102, 1038

Sorted by citations

Items 301–400 of 899

Exendin-4 induces myocardial protection through MKK3 and Akt-1 in infarcted hearts
Du, J., Zhang, L., Wang, Z., Yano, N., Zhao, Y., Lei, W., Dubielecka, P. M., Liu, P. Y., Zhuang, S., Qin, G., et al. (2016) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00194.2015 · Cited by 44
Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial
Awal, H. B., Nandula, S. R., Domingues, C. C., Dore, F. J., Kundu, N., Břicháček, B., Fakhri, M., Elzarki, A., Ahmadi, N., Safai, S., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01046-z · Cited by 43
Oxidation of Protein Kinase A Regulatory Subunit PKARIα Protects Against Myocardial Ischemia-Reperfusion Injury by Inhibiting Lysosomal-Triggered Calcium Release
Simon, J. N., Vrellaku, B., Monterisi, S., Chu, S. M., Rawlings, N., Lomas, O., Marchal, G. A., Waithe, D., Syeda, F., Gajendragadkar, P. R., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.046761 · Cited by 43
Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands
Tanday, N., Flatt, P. R., & Irwin, N. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15485 · Cited by 48
Systematic Understanding of Pathophysiological Mechanisms of Oxidative Stress-Related Conditions—Diabetes Mellitus, Cardiovascular Diseases, and Ischemia–Reperfusion Injury
Wang, M., Liu, Y., Liang, Y. T., Naruse, K., & Takahashi, K. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.649785 · Cited by 46
A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review
Tilinca, M. C., Tiucă, R. A., Burlacu, A., & Varga, A. (2021) · Medicina · doi:10.3390/medicina57070669 · Cited by 45
Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
Petersen, B., & Christensen, M. (2013) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s45379 · Cited by 41
Acute-Phase Glucose Fluctuation Is Negatively Correlated With Myocardial Salvage After Acute Myocardial Infarction
Teraguchi, I., Imanishi, T., Ozaki, Y., Tanimoto, T., Ueyama, M., Orii, M., Shiono, Y., Shimamura, K., Ishibashi, K., Yamano, T., et al. (2013) · Circulation Journal · doi:10.1253/circj.cj-13-0723 · Cited by 42
Therapeutic targets to reduce cardiovascular disease in type 2 diabetes
Desouza, C. V., & Fonseca, V. A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2872 · Cited by 42
Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies
Li, L., Li, S., Liu, J., Deng, K., Busse, J. W., Vandvik, P. O., Wong, E. M., Sohani, Z. N., Bała, M. M., Rios, L. P., et al. (2016) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0260-0 · Cited by 41
After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?
Vergès, B. L., & Charbonnel, B. H. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30067-8 · Cited by 43
Effect of continuous exenatide infusion on cardiac function and peri-operative glucose control in patients undergoing cardiac surgery: A single-blind, randomized controlled trial
Lipš, M., Mráz, M., Kloučková, J., Kopecký, P., Dobiáš, M., Křížová, J., Lindner, J., Diamant, M., & Haluzík, M. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13029 · Cited by 39
Improved diastolic function in type 2 diabetes after a six month liraglutide treatment
Saponaro, F., Sonaglioni, A., Rossi, A., Montefusco, L., Lombardo, M., Adda, G., & Arosio, M. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.04.046 · Cited by 41
Extraglycemic effects of glp-1-based therapeutics: Addressing metabolic and cardiovascular risks associated with type 2 diabetes
Herzlinger, S., & Horton, E. S. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.11.009 · Cited by 43
Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: A pairwise and network meta-analysis
Sun, F., Yu, K., Wu, S., Zhang, Y., Yang, Z., Shi, L., Ji, L., & Zhan, S. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.09.004 · Cited by 41
Is Incretin-Based Therapy Ready for the Care of Hospitalized Patients With Type 2 Diabetes?
Schwartz, S. S., & DeFronzo, R. A. (2013) · Diabetes Care · doi:10.2337/dc12-2060 · Cited by 40
GLP‐1 and insulin regulation of skeletal and cardiac muscle microvascular perfusion in type 2 diabetes
Love, K. M., Liu, J., Regensteiner, J. G., Reusch, J. E. B., & Liu, Z. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13045 · Cited by 40
Antidiabetic gliptins in combination with G-CSF enhances myocardial function and survival after acute myocardial infarction
Theiss, H. D., Groß, L., Vallaster, M., David, R., Brunner, S., Brenner, C., Nathan, P., Assmann, G., Mueller‐Hoecker, J., Vogeser, M., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.04.121 · Cited by 40
Myocardial structure, function and ischaemic tolerance in a rodent model of obesity with insulin resistance
Wensley, I., Salaveria, K., Bulmer, A. C., Donner, D. G., & Toit, E. F. D. (2013) · Experimental Physiology · doi:10.1113/expphysiol.2013.074948 · Cited by 40
Pleiotropic Actions of the Incretin Hormones
McIntosh, C. H. S., Widenmaier, S. B., & Kim, S. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00002-3 · Cited by 42
Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance
Abdesselam, I., Pepino, P., Troalen, T., Macia, M., Ancel, P., Masi, B., Fourny, N., Gaborit, B., Giannesini, B., Kober, F., et al. (2015) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/s12968-015-0198-x · Cited by 42
An interaction between glucagon-like peptide-1 and adenosine contributes to cardioprotection of a dipeptidyl peptidase 4 inhibitor from myocardial ischemia-reperfusion injury
Ihara, M., Asanuma, H., Yamazaki, S., Kato, H., Asano, Y., Shinozaki, Y., Mori, H., Minamino, T., Asakura, M., Sugimachi, M., et al. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00835.2014 · Cited by 42
Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus
Holst, J. J., & McGill, M. A. (2011) · Clinical Drug Investigation · doi:10.2165/11595370-000000000-00000 · Cited by 40
Encapsulated Glucagon-Like Peptide-1-Producing Mesenchymal Stem Cells Have a Beneficial Effect on Failing Pig Hearts
Wright, E. J., Farrell, K., Malik, N., Kassem, M. S., Lewis, A. L., Wallrapp, C., & Holt, C. M. (2012) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0064 · Cited by 40
Antidiabetic GLP-1 Receptor Agonists Have Neuroprotective Properties in Experimental Animal Models of Alzheimer’s Disease
Urkon, M., Ferencz, E., Szász, J. A., Szabó, M. I. M., Orbán-Kis, K., Szatmári, S., & Nagy, E. E. (2025) · Pharmaceuticals · doi:10.3390/ph18050614 · Cited by 43
Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity/Mortality? Yes
Bianchi, C., Miccoli, R., Daniele, G., Penno, G., & Prato, S. D. (2009) · Diabetes Care · doi:10.2337/dc09-s336 · Cited by 40
Association of Antidiabetic Medications Targeting the Glucagon-Like Peptide 1 Pathway and Heart Failure Events in Patients With Diabetes
Velez, M., Peterson, E. L., Wells, K. E., Swadia, T. V., Sabbah, H. N., Williams, L. K., & Lanfear, D. E. (2014) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2014.10.012 · Cited by 40
Effect of Hypoglycemic Agents on Ischemic Preconditioning in Patients With Type 2 Diabetes and Symptomatic Coronary Artery Disease
Garcia, R. M. R., Uchida, A. H., Rezende, P. C., Lima, E. G., Garzillo, C. L., Favarato, D., Strunz, C. M. C., Takiuti, M. E., Girardi, P. B. M. A., Hueb, W. A., et al. (2012) · Diabetes Care · doi:10.2337/dc12-1495 · Cited by 39
Glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase IV inhibitors: new therapeutic agents for the treatment of type 2 diabetes
Sinclair, E. M., & Drucker, D. J. (2005) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000155379.11926.e2 · Cited by 39
Clinical Effectiveness of Intravenous Exenatide Infusion in Perioperative Glycemic Control after Coronary Artery Bypass Graft Surgery: A Phase II/III Randomized Trial
Besch, G., Perrotti, A., Mauny, F., Puyraveau, M., Baltres, M., Flicoteaux, G., Salomon du Mont, L., Barrucand, B., Samain, E., Chocron, S., et al. (2017) · Anesthesiology · doi:10.1097/aln.0000000000001838 · Cited by 38
Glucagon-Like Peptide-1 Receptor Agonists for Diabetes Mellitus
Smilowitz, N. R., Donnino, R. M., & Schwartzbard, A. Z. (2014) · Circulation · doi:10.1161/circulationaha.113.006985 · Cited by 40
Congestive Heart Failure and Diabetes Mellitus: Balancing Glycemic Control with Heart Failure Improvement
Nasir, S., & Aguilar, D. A. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.031 · Cited by 39
Cardiovascular safety and benefits of GLP-1 receptor agonists
Dalsgaard, N. B., Brønden, A., Vilsbøll, T., & Knop, F. K. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1281246 · Cited by 37
Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction
Qi, Q., Lu, L., Li, H., Yuan, Z., Chen, G., Lin, M., Ruan, Z., Ye, X., Xiao, Z., & Zhao, Q. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s132064 · Cited by 38
Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients
Saraiva, J. F. K., & Franco, D. R. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01417-0 · Cited by 39
Diabetic nephropathy: protective factors and a new therapeutic paradigm
Mima, A. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.03.003 · Cited by 37
Confronting the Type 2 Diabetes Epidemic: the Emerging Role of Incretin-Based Therapies
Fonseca, V. A., Zinman, B., Nauck, M. A., Goldfine, A. B., & Plutzky, J. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.04.002 · Cited by 37
Glucagon-like peptide-1 regulates calcium homeostasis and electrophysiological activities of HL-1 cardiomyocytes
Huang, J.-H., Chen, Y.-C., Lee, T.-I., Kao, Y.-H., Chazo, T.-F., Chen, S.-A., & Chen, Y.-J. (2016) · Peptides · doi:10.1016/j.peptides.2016.02.007 · Cited by 36
Incretin drugs as modulators of atherosclerosis
Gallego-Colon, E., Wojakowski, W., & Francuz, T. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.09.011 · Cited by 35
Type 2 Diabetes: An Expanded View of Pathophysiology and Therapy
Unger, J., & Parkin, C. G. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.05.2152 · Cited by 36
Pleiotropic effects of incretins
Gupta, V. (2012) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.94259 · Cited by 37
Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
Fadini, G. P., & Rigato, M. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s37644 · Cited by 39
Pharmacological management of type 2 diabetes: the potential of incretin‐based therapies
Charbonnel, B. H., & Cariou, B. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01317.x · Cited by 37
Incretin-based therapies and cardiovascular risk
Mannucci, E., & Dicembrini, I. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.678940 · Cited by 35
Incretin Therapies: Effects Beyond Glycemic Control
Mudaliar, S. R. D., & Henry, R. R. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.014 · Cited by 35
Intracoronary Infusion of Encapsulated Glucagon-Like Peptide-1–Eluting Mesenchymal Stem Cells Preserves Left Ventricular Function in a Porcine Model of Acute Myocardial Infarction
de Jong, R., van Hout, G. P. J., Houtgraaf, J. H., Kazemi, K., Wallrapp, C., Lewis, A. L., Pasterkamp, G., Hoefer, I. E., & Duckers, H. J. (2014) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.114.001580 · Cited by 35
Exenatide Reduces Tumor Necrosis Factor-α-induced Apoptosis in Cardiomyocytes by Alleviating Mitochondrial Dysfunction
Cao, Y., Chen, Z., Gao, Y., Wang, X.-X., Ma, J., Chang, S., Qian, J., & Ge, J. (2015) · Chinese Medical Journal · doi:10.4103/0366-6999.170259 · Cited by 36
The Glucoregulatory Benefits of Glucagon-Like Peptide-1 (7-36) Amide Infusion During Intensive Insulin Therapy in Critically Ill Surgical Patients
Galiatsatos, P., Gibson, B. R., Rabiee, A., Carlson, O. D., Egan, J. M., Shannon, R. P., Andersen, D. K., & Elahi, D. (2013) · Critical Care Medicine · doi:10.1097/ccm.0000000000000035 · Cited by 35
Self-citation
RETRACTED: Cilostazol protects mice against myocardium ischemic/reperfusion injury by activating a PPARγ/JAK2/STAT3 pathway
Li, J., Xiang, X., Gong, X., Shi, Y., Yang, J., & Xu, Z. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.07.143 · Cited by 35
Retracted
Glucagon-Like Peptide-1
Giblett, J. P., Clarke, S. J., Dutka, D. P., & Hoole, S. P. (2016) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2016.03.011 · Cited by 36
Liraglutide Improves Glycemic and Blood Pressure Control and Ameliorates Progression of Left Ventricular Hypertrophy in Patients with Type 2 Diabetes Mellitus on Peritoneal Dialysis
Hiramatsu, T., Ozeki, A., Asai, K., Saka, M., Hobo, A., & Furuta, S. (2015) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12319 · Cited by 34
Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential
Røder, M. E. (2017) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622317735283 · Cited by 34
Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies
Brown, N. J. (2012) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2012.02.003 · Cited by 34
Exenatide as a treatment for diabetes and obesity: Implications for cardiovascular risk reduction
Mafong, D. D., & Henry, R. R. (2008) · Current Atherosclerosis Reports · doi:10.1007/s11883-008-0009-z · Cited by 34
Glucagon-Like Peptide-1 Counteracts Oxidative Stress-Dependent Apoptosis of Human Cardiac Progenitor Cells by Inhibiting the Activation of the c-Jun N-terminal Protein Kinase Signaling Pathway
Laviola, L., Leonardini, A., Melchiorre, M., Orlando, M. R., Peschechera, A., Bortone, A. S., Paparella, D., Natalicchio, A., Perrini, S., & Giorgino, F. (2012) · Endocrinology · doi:10.1210/en.2012-1461 · Cited by 35
GLP-1 Therapy
Hausenloy, D. J., & Yellon, D. M. (2008) · Circulation Heart Failure · doi:10.1161/circheartfailure.108.810887 · Cited by 35
Gastric Bypass Surgery Elevates NT-ProBNP Levels
Abrahamsson, N., Engström, B. E., Sundbom, M., & Karlsson, F. A. (2013) · Obesity Surgery · doi:10.1007/s11695-013-0889-z · Cited by 33
Selective targeting of glucagon‐like peptide‐1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes
Tate, M., Chong, A., Robinson, E., Green, B. D., & Grieve, D. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12943 · Cited by 33
Extra-pancreatic effects of incretin-based therapies
Gallwitz, B. (2014) · Endocrine · doi:10.1007/s12020-014-0223-0 · Cited by 32
Exenatide modulates metalloproteinase expression in human cardiac smooth muscle cells via the inhibition of Akt signaling pathway
Gallego-Colón, E., Kłych‐Ratuszny, A., Kosowska, A., Garczorz, W., Aghdam, M. R. F., Woźniak, M., & Francuz, T. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.10.003 · Cited by 33
Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease—State of the Art
Jonik, S., Marchel, M., Grabowski, M., Opolski, G., & Mazurek, T. (2022) · Biology · doi:10.3390/biology11020288 · Cited by 33
Impact of intravenous exenatide infusion for perioperative blood glucose control on myocardial ischemia-reperfusion injuries after coronary artery bypass graft surgery: sub study of the phase II/III ExSTRESS randomized trial
Besch, G., Perrotti, A., du Mont, L. S., Puyraveau, M., Ben-Said, X., Baltres, M., Barrucand, B., Flicoteaux, G., Vettoretti, L., Samain, E., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0784-y · Cited by 33
Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in coronary artery disease: a comprehensive review
Skrobucha, A., Pindlowski, P., Krajewska, N., Grabowski, M., & Jonik, S. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1446468 · Cited by 32
Lethal myocardial reperfusion injury: a necessary evil?
Ibáñez, B., Fuster, V., Jiménez-Borreguero, J., & Badimón, J. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.10.056 · Cited by 37
Exendin-4 promotes endothelial barrier enhancement via PKA- and Epac1-dependent Rac1 activation
Li, A. Q., Zhao, L., Zhou, T. F., Zhang, M. Q., & Qin, X. M. (2014) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00249.2014 · Cited by 33
Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study
Ida, S., Murata, K., Betou, K., Kobayashi, C., Ishihara, Y., Imataka, K., Uchida, A., Monguchi, K., Kaneko, R., Fujiwara, R., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0468-4 · Cited by 32
Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus
Vijayakumar, S., Vaduganathan, M., & Butler, J. (2018) · Circulation · doi:10.1161/circulationaha.117.032099 · Cited by 32
Obesity-related cardiorenal disease: the benefits of bariatric surgery
Fenske, W., Athanasiou, T., Harling, L., Drechsler, C., Darzi, A. W., & Ashrafian, H. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.145 · Cited by 32
Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial)
Marso, S. P., Nauck, M. A., Fries, T. M., Rasmussen, S., Treppendahl, M. B., & Buse, J. B. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.02.030 · Cited by 32
Gut Hormones as Potential New Targets for Appetite Regulation and the Treatment of Obesity
Field, B. C. T., Wren, A., Cooke, D., & Bloom, S. R. (2008) · Drugs · doi:10.2165/00003495-200868020-00002 · Cited by 33
The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action
Alexiadou, K., Hartley, A., Tan, T. M.-M., & Khamis, R. (2024) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2024.03.003 · Cited by 31
Glucagon and a glucagon‐GLP‐1 dual‐agonist increases cardiac performance with different metabolic effects in insulin‐resistant hearts
Axelsen, L. N., Keung, W., Pedersen, H. D., Meier, E., Riber, D., Kjølbye, A. L., Petersen, J., Proctor, S. D., Holstein‐Rathlou, N., & Lopaschuk, G. D. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01714.x · Cited by 34
Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs
Sjöholm, Å. (2010) · Pharmaceuticals · doi:10.3390/ph3030764 · Cited by 31
Comparison of liraglutide versus other incretin‐related anti‐hyperglycaemic agents
Blonde, L., & Montanya, E. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01575.x · Cited by 31
Diabetes and Cardiovascular Disease: The Potential Benefit of Incretin-Based Therapies
Addison, D., & Aguilar, D. A. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0153-0 · Cited by 32
A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study)
Jorsal, A., Wiggers, H., Holmager, P., Nilsson, B., Nielsen, R. R., Boesgaard, T. W., Kumme, A., Møller, J. E., Videbæk, L. M., Kistorp, C., et al. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-004885 · Cited by 29
Evaluating Second-Line Treatment Options for Type 2 Diabetes: Focus on Secondary Effects of GLP-1 Agonists and DPP-4 Inhibitors
Boland, C. L., DeGeeter, M., Nuzum, D. S., & Tzefos, M. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r444 · Cited by 32
Inhibition of DPP-4 by alogliptin improves coronary flow reserve and left ventricular systolic function evaluated by phase contrast cine magnetic resonance imaging in patients with type 2 diabetes and coronary artery disease
Kato, S., Fukui, K., Kirigaya, H., Gyotoku, D., Iinuma, N., Kusakawa, Y., Iguchi, K., Nakachi, T., Iwasawa, T., & Kimura, K. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.08.306 · Cited by 31
Cardiovascular Protection with Anti-hyperglycemic Agents
DEEDWANIA, P. C., & Acharya, T. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00325-9 · Cited by 31
Cardiometabolism as an Interlocking Puzzle between the Healthy and Diseased Heart: New Frontiers in Therapeutic Applications
Pasqua, T., Rocca, C., Giglio, A., & Angelone, T. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040721 · Cited by 31
A Meta-Analysis of the Therapeutic Effects of Glucagon-Like Peptide-1 Agonist in Heart Failure
Munaf, M., Pellicori, P., Allgar, V. L., & Wong, K. (2012) · International Journal of Peptides · doi:10.1155/2012/249827 · Cited by 31
Dipeptidyl peptidase‐4 inhibition improves cardiac function in experimental myocardial infarction: Role of stromal cell‐derived factor‐1α
Connelly, K. A., Advani, A., Zhang, Y., Advani, S. L., Kabir, G., Abadeh, A., Desjardins, J., Mitchell, M., Thai, K., & Gilbert, R. E. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12258 · Cited by 30
Non‐glycaemic effects mediated via GLP‐1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide
Vilsbøll, T., & Garber, A. J. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01579.x · Cited by 30
Cardiovascular Actions of GLP-1 and Incretin-Based Pharmacotherapy
Avogaro, A., de Kreutzenberg, S. V., & Fadini, G. P. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0483-3 · Cited by 30
Postconditioning with glucagon like peptide-2 reduces ischemia/reperfusion injury in isolated rat hearts: role of survival kinases and mitochondrial KATP channels
Penna, C. R. R., Pasqua, T., Perrelli, M.-G., Pagliaro, P., Cerra, M. C., & Angelone, T. (2012) · Basic Research in Cardiology · doi:10.1007/s00395-012-0272-6 · Cited by 30
Reduced Cardio-Renal Function Accounts for Most of the In-Hospital Morbidity and Mortality Risk Among Patients With Type 2 Diabetes Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction
Marenzi, G., Cosentino, N., Genovese, S., Campodonico, J., Metrio, M. D., Rondinelli, M., Cornara, S., Somaschini, A., Camporotondo, R., Demarchi, A., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0047 · Cited by 29
Dipeptidyl Peptidase-4 Inhibitor
Murohara, T. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.09.050 · Cited by 30
Safety and Efficacy of GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus with Advanced and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis
Krisanapan, P., Sanpawithayakul, K., Pattharanitima, P., Thongprayoon, C., Miao, J., Mao, M. A., Suppadungsuk, S., Tangpanithandee, S., Craici, I. M., & Cheungpasitporn, W. (2024) · Diseases · doi:10.3390/diseases12010014 · Cited by 31
Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors
Gallwitz, B. (2013) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018813486165 · Cited by 20
Cardiac structure and function before and after bariatric surgery: a clinical overview
Lascaris, B., Pouwels, S., Houthuizen, P., Dekker, L., Nienhuijs, S. W., Bouwman, R. A., & Buise, M. P. (2018) · Clinical Obesity · doi:10.1111/cob.12278 · Cited by 29
Cardiovascular outcome trials of the newer anti-diabetic medications
Acharya, T., & DEEDWANIA, P. C. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.08.003 · Cited by 29
Future perspectives in diabesity treatment: Semaglutide, a glucagon‑like peptide 1 receptor agonist (Review)
Tilinca, M. C., Tiucă, R. A., Niculas, C., Varga, A., & Ţilea, I. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10601 · Cited by 30
Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes
Schnabel, C. A., Wintle, M. E., & Kolterman, O. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.1.69 · Cited by 29
Alogliptin improves survival and health of mice on a high‐fat diet
Zhu, B., Li, Y., Xiang, L., Zhang, J., Wang, L., Guo, B., Liang, M., Chen, L., Xiang, L., Dong, J., et al. (2019) · Aging Cell · doi:10.1111/acel.12883 · Cited by 29
Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists
Madsbad, S., & Holst, J. J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac112 · Cited by 37
Dipeptidyl peptidase‐4 inhibitors: Multitarget drugs, not only antidiabetes drugs (D ipeptidyl peptidase ‐4抑制剂：多靶点药物，不仅仅是降糖药)
Zhao, Y., Yang, L., & Zhou, Z. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12063 · Cited by 28
The stem cell adjuvant with Exendin‐4 repairs the heart after myocardial infarction via STAT 3 activation
Liu, J., Wang, H., Wang, Y., Yin, Y., Du, Z., Liu, Z., Yang, J., Hu, S., Wang, C., & Chen, Y. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12272 · Cited by 28
Cardioprotective effects of incretin during ischaemia-reperfusion
Chinda, K., Chattipakorn, S. C., & Chattipakorn, N. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112440816 · Cited by 28
Association of glucagon‐like peptide‐1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system
Zimmerman, R. S., Hobbs, T. M., Wells, B. J., Kong, S. X., Kattan, M. W., Bouchard, J. R., Chagin, K. M., Yu, C., Sakurada, B., Milinovich, A., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12969 · Cited by 28
Mechanisms for the cardiovascular effects of glucagon-like peptide-1
Poudyal, H. (2015) · Acta Physiologica · doi:10.1111/apha.12604 · Cited by 27

Authors: Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P.
Affiliations: Allegheny General Hospital (US)
ORCID: Nikolaidis, Lazaros A.
Mankad, Sunil
Sokos, George G.
Venue: Circulation
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2004-03-02
Volume: 109
Issue: 8
Pages: 962-965
ISSN: 0009-7322 (ISSN-L)
1524-4539
DOI: 10.1161/01.cir.0000120505.91348.58
OpenAlex: W1968315455
Cited by: 901
References: 15
Citations by year: 2026: 9 · 2025: 16 · 2024: 25 · 2023: 18 · 2022: 17 · 2021: 25 · 2020: 27 · 2019: 38 · 2018: 37 · 2017: 46 · 2016: 48 · 2015: 63 · 2014: 71 · 2013: 80 · 2012: 92
FWCI: 16.30
Type: journal article
Language: en
Open access: closed
Locations: Circulation (publishedVersion)
PubMed (publishedVersion)
Funders: Pittsburgh Foundation
National Institutes of Health (5r01ag023125-05)
National Institute on Aging (1 R01 AG023125)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Ischemia and Reperfusion
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords: glucagon-like peptide-1, acute myocardial infarction, left ventricular dysfunction, primary percutaneous coronary intervention, reperfusion, left ventricular ejection fraction, regional wall motion, incretin-based therapy, glucose-insulin-potassium infusion, systolic dysfunction
MeSH terms: Adult, Aged, Aged, 80 and over, Blood Glucose, Combined Modality Therapy, Glucagon-Like Peptides, Female, Glucagon, Humans, Male, Middle Aged, Myocardial Infarction, Peptide Fragments, Pilot Projects, Safety, Stroke Volume, Angioplasty, Balloon, Coronary, Ventricular Function, Left, Treatment Outcome, Diabetes Complications, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks